Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
65 hedge funds and large institutions have $304M invested in Oxford Immunotec Global PLC Ordinary Shares in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 13 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
35% more capital invested
Capital invested by funds: $225M → $304M (+$79.6M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
0% more funds holding
Funds holding: 65 → 65 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$8.3M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.91M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.24M |
| 4 |
Millennium Management
New York
|
+$3.01M |
| 5 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$25.1M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$11.5M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$3.59M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.47M |
| 5 |
KOCAA
Knights of Columbus Asset Advisors
New Haven,
Connecticut
|
-$1.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QCG
76
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$4K | -404 | Closed |
|
77
UBS Group
Zurich,
Switzerland
| – | -$1K | -145 | Closed |
|
78
BNP Paribas Financial Markets
Paris,
France
| – | -$194 | -21 | Closed |
|
OXFD Hedge Fund Activity: Q2 2020 in Review
65 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q2 2020, worth a combined $304M — up 35% from $225M a quarter earlier.
Fund positioning in OXFD was balanced in Q2 2020: 13 funds opened new positions, 13 closed out, 26 added to existing stakes and 19 trimmed.
The largest buyer was Deerfield Management, adding an estimated $8.3M. The largest seller was Invesco, cutting an estimated $25.1M.
- 65 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $304M of Oxford Immunotec Global PLC Ordinary Shares stock for Q2 2020, up 35% quarter-over-quarter.
- 13 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q2 2020 and 13 closed out, a net change of 0 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q2 2020 was Deerfield Management, an estimated $8.3M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q2 2020 was Invesco, an estimated $25.1M sold.
Based on aggregated 13F filings for Q2 2020.